United States Patent 7,968,569: Lenalidomide Multiple Myeloma Claims, Patent Scope, Expiration, and Generic Risk

U.S. Patent 7,968,569 protects a specific Revlimid-style treatment regimen using lenalidomide, or a pharmaceutically acceptable salt, with dexamethasone for multiple myeloma. The central protected regimen is 5 to 25 mg of lenalidomide daily for 21 consecutive days, followed by seven days without lenalidomide, in a recurring 28-day cycle. Claim 13 narrows the regimen to 25 mg on days 1 through 21 and 40 mg of dexamethasone on days 1 through 4 of each cycle.

The patent is a method-of-use patent, not the core chemical-composition patent for lenalidomide. Its commercial relevance is tied to Revlimid and generic lenalidomide products that copy or rely on the patented multiple myeloma dosing regimen.

What drug does U.S. Patent 7,968,569 cover?

The compound recited by the patent is lenalidomide, chemically known as 3-(4-amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione. Lenalidomide is the active pharmaceutical ingredient in Revlimid, marketed by Bristol Myers Squibb following its acquisition of Celgene.

The patent claims the compound itself only as part of a treatment method. It does not claim broad ownership of every lenalidomide product or every use of lenalidomide. The principal statutory categories are:

Category	Scope under U.S. Patent 7,968,569
Active ingredient	Lenalidomide or a pharmaceutically acceptable salt
Disease	Multiple myeloma
Dose	About 5 to about 25 mg per day in the broadest regimen claim
Cycle	21 consecutive treatment days followed by 7 days of rest
Combination agent	Dexamethasone at 40 mg per day
Administration	Oral administration expressly covered by dependent claims
Dosage form	Capsules and tablets
Specific strengths	5 mg, 10 mg, 15 mg and 25 mg capsules
Patient population	Includes relapsed, refractory and resistant multiple myeloma
Cycle duration	28 days under claim 13

The patent is therefore directed at a clinically defined regimen rather than at lenalidomide chemistry, manufacturing, polymorphism or formulation technology.

What are the independent claims of U.S. Patent 7,968,569?

Claims 1 and 13 are the principal independent claims.

Claim 1: broad 21-days-on, seven-days-off regimen

Claim 1 covers a method of treating a patient with multiple myeloma by:

Administering approximately 5 to 25 mg per day of lenalidomide or a pharmaceutically acceptable salt;
Continuing treatment for 21 consecutive days;
Following treatment with seven days of rest from lenalidomide; and
Administering the treatment in combination with 40 mg per day of dexamethasone.

Claim 1 is broad in disease status and dosage within the 5 to 25 mg range. It does not expressly limit the patient to relapsed or refractory disease, although those populations are expressly covered by dependent claims.

The wording supplied for claim 1 states "followed by seven in combination with 40 mg per day dexamethasone." The patent's intended regimen is seven days of rest from lenalidomide. Claim 13 states that limitation more clearly.

Claim 13: 25 mg and scheduled dexamethasone regimen

Claim 13 covers a 28-day cycle consisting of:

Lenalidomide at approximately 25 mg per day for 21 consecutive days;
Seven consecutive days without lenalidomide; and
Dexamethasone at 40 mg per day on days 1 through 4 of each 28-day cycle.

Claim 13 is narrower than claim 1 but is closely aligned with the original Revlimid regimen used in relapsed or refractory multiple myeloma. A product label or clinical protocol that directs this exact regimen presents the clearest risk of infringement.

How do the dependent claims expand the patent scope?

The dependent claims cover patient subgroups, dose levels, dosage forms and excipient compositions.

Claim	Limitation
2	Smoldering, indolent, chemotherapy-responsive, refractory, relapsed or relapsed and refractory Durie-Salmon stage III multiple myeloma
3	Pharmaceutically acceptable salt
4	Disease relapsed, refractory or resistant to previous therapy
5	Lenalidomide and dexamethasone administered orally
6	Capsule or tablet administration
7	Lenalidomide dose of approximately 10 to 25 mg per day
8	Approximately 5, 10, 20 or 25 mg per day
9	Approximately 25 mg per day
10	5 mg per day
11	10 mg per day
12	Capsules containing 5, 10, 15 or 25 mg
14	Capsule containing lenalidomide, anhydrous lactose, microcrystalline cellulose, croscarmellose sodium and magnesium stearate
15	Dexamethasone is administered

Claim 14 is particularly relevant to finished-product analysis. It requires a capsule containing the specified excipients. A generic product with materially different excipients may avoid claim 14 while remaining exposed to broader method claims.

Claim 15 adds little practical protection because claim 1 already requires treatment "in combination with 40 mg per day dexamethasone." Its significance would depend on claim construction and the exact relationship between the claims in an infringement action.

What multiple myeloma populations are protected?

The patent covers a broad range of multiple myeloma populations through claim 2 and claim 4. The express categories include:

Smoldering myeloma;
Indolent myeloma;
Chemotherapy-responsive multiple myeloma;
Refractory multiple myeloma;
Relapsed multiple myeloma;
Relapsed and refractory multiple myeloma;
Disease resistant to prior therapy; and
Relapsed and refractory Durie-Salmon stage III multiple myeloma.

The broadest claims do not require a particular stage or prior-treatment history. A product label that recommends the regimen for multiple myeloma generally can create a different type of risk from a label limited to an unpatented population. The relevant legal question is whether the product labeling, promotional conduct or prescribing pathway induces use of the patented regimen.

What doses and dosage forms are protected?

The patent covers a clinically important dose range.

Dose coverage

The dose limitations include:

Approximately 5 to 25 mg per day;
Approximately 10 to 25 mg per day;
Approximately 5, 10, 20 or 25 mg per day;
Exactly 5 mg per day under claim 10;
Exactly 10 mg per day under claim 11; and
Approximately 25 mg per day under claim 9 and claim 13.

The 15 mg strength is not separately stated as a daily dose in the claims, but claim 12 expressly covers capsules in 5 mg, 10 mg, 15 mg and 25 mg strengths.

Oral and capsule limitations

Claims 5 and 6 expressly cover oral administration and capsule or tablet dosage forms. Claim 14 adds the specified excipient combination:

Lenalidomide;
Anhydrous lactose;
Microcrystalline cellulose;
Croscarmellose sodium; and
Magnesium stearate.

A generic capsule may infringe a method claim even if it does not use the same excipient composition. Conversely, a different formulation may avoid claim 14 but not avoid claims 1, 4, 5 or 13.

What is the Orange Book status of U.S. Patent 7,968,569?

U.S. Patent 7,968,569 has been listed in the FDA Orange Book for Revlimid in connection with lenalidomide use in multiple myeloma. It is a use patent rather than a composition-of-matter patent.

The Orange Book listing is important because an abbreviated new drug application applicant that seeks approval for a listed patented use must address the patent through a Paragraph IV certification if it contends that the patent is invalid, unenforceable or will not be infringed. The applicant may also pursue a section viii statement and omit the patented use where the proposed labeling legally supports such an omission. The availability of a section viii pathway depends on the patent listing, approved labeling and the proposed product's label.

FDA listing does not establish validity or infringement. Those questions are determined under the Patent Act and, where litigated, by the courts.

When does U.S. Patent 7,968,569 expire?

The patent has a listed expiration date in the December 2027 period. Public patent records and Orange Book data associate U.S. Patent 7,968,569 with an expiration date of December 27, 2027, subject to any applicable patent-term adjustment or pediatric extension reflected in the controlling FDA and USPTO records.

The patent issued on July 5, 2011. Its commercial blocking period must be analyzed together with other Revlimid patents, settlement agreements and any authorized generic or license arrangements. The expiration of this patent alone does not determine the earliest lawful generic launch date.

The core lenalidomide composition patent and other method, formulation and manufacturing patents have separate expiration dates and legal scopes. Some important Revlimid patents run into 2027, which creates a layered exclusivity structure rather than a single patent cliff. [1][2]

What Paragraph IV challenges affected Revlimid and lenalidomide?

Generic applicants challenged Revlimid patents through Paragraph IV certifications. The principal challengers included major generic companies such as Natco, Teva, Dr. Reddy's Laboratories, Cipla, Zydus and other ANDA sponsors.

The challenges generally addressed one or more of the following positions:

The asserted patent claims are invalid;
The proposed generic product does not infringe;
The patent is unenforceable;
The applicant's label does not induce the patented use; or
The applicant can enter under an agreed license date.

Celgene brought patent litigation against multiple ANDA applicants. The litigation involved core lenalidomide patents and additional Revlimid patents covering dosing, formulations, methods of treatment and risk-management controls. Several disputes were resolved through settlements that permitted limited or staged generic entry before complete patent expiry. [3][4]

A Paragraph IV filing is not itself evidence that a patent will fail. It creates litigation exposure and can trigger a 30-month stay of FDA approval under the Hatch-Waxman Act if the branded sponsor sues within the statutory period.

What generic launch risks exist for lenalidomide?

Generic launch risk is divided into three periods:

Period	Principal risk
Before settlement-authorized entry	Paragraph IV litigation, 30-month stay and possible injunction
During limited settlement entry	Restricted volume, license limits, allocation controls and product-specific launch dates
After patent expiry or license release	Broad generic competition and loss of branded volume

The most important commercial distinction is between technical approval and unrestricted market entry. An ANDA may be approved while the applicant remains subject to a settlement license, a patent injunction or contractual launch restrictions.

Generic lenalidomide products may also be subject to the Revlimid Risk Evaluation and Mitigation Strategy, or REMS, depending on the FDA's applicable requirements and the approved product's implementation arrangements. FDA approval does not eliminate the requirement to comply with the applicable safety-program obligations. [5]

How strong is the patent estate around Revlimid?

The 7,968,569 patent is commercially meaningful but narrower than the lenalidomide composition patent. Its strength comes from the fact that it covers the dosing regimen used in the principal multiple myeloma market.

Strengths

It covers the standard 21-days-on, seven-days-off cycle.
It covers the commonly used 25 mg dose.
It expressly covers combination treatment with dexamethasone.
It reaches relapsed and refractory multiple myeloma.
It includes oral capsules and tablets.
It aligns with the labeled clinical use of Revlimid.

Limitations

It is a method-of-treatment patent.
It does not independently prevent all lenalidomide manufacture or sale.
Some claims use approximate language such as "about."
Non-infringing labeling and prescribing theories may reduce inducement exposure.
Alternative dosing schedules may fall outside specific claims, although the commercial and clinical viability of those alternatives must be assessed separately.
Claim 14 depends on a particular excipient combination and is easier to design around than the broader regimen claims.

The strongest claims for commercial enforcement are claims 1, 4, 5, 7, 8, 9 and 13. Claim 13 is the clearest claim against a product whose labeling expressly reproduces the 25 mg, 21/7 regimen with dexamethasone on days 1 through 4.

What other patents cover lenalidomide and Revlimid?

The patent landscape includes several layers.

Composition-of-matter patents

The foundational lenalidomide patent family protects the active compound and related chemical subject matter. U.S. Patent 5,635,517 is commonly identified as a key composition patent for lenalidomide. Composition claims are generally more difficult to design around than method claims because they attach to the active ingredient itself. [6]

Method-of-use patents

Method patents cover:

Multiple myeloma;
Myelodysplastic syndromes;
Mantle cell lymphoma;
Other hematologic malignancies;
Specific dose schedules;
Combination therapy; and
Patient populations such as relapsed or refractory patients.

U.S. Patent 7,968,569 belongs to this category.

Formulation patents

Formulation patents may cover:

Capsule dosage forms;
Excipient combinations;
Dissolution or stability characteristics;
Specific particle or solid-state properties; and
Manufacturing processes for pharmaceutical compositions.

Claim 14 is the relevant formulation-type claim in this patent, although it is framed as a dependent method claim rather than as a broad composition claim.

Manufacturing and process patents

Separate rights may cover the synthesis of lenalidomide, intermediates, purification processes, crystallization, polymorphs and commercial-scale production. These rights can affect supply-chain freedom to operate even after a method-of-use patent becomes less important.

Geographic coverage

U.S. Patent 7,968,569 has no automatic effect outside the United States. Foreign counterparts must be reviewed separately by jurisdiction. European, Canadian, Japanese, Australian and other national rights may have different claims, expiration dates, prosecution histories and litigation outcomes.

How does U.S. Patent 7,968,569 compare with the core lenalidomide patent?

Issue	U.S. Patent 7,968,569	Core lenalidomide composition patent
Patent type	Method of treatment	Chemical composition
Protected subject matter	Specific multiple myeloma regimen	Lenalidomide compound and related chemistry
Infringement focus	Use, labeling and prescribing	Making, using, selling or importing the compound
Design-around potential	Relatively higher	Relatively lower
Commercial relevance	Protects the Revlimid regimen	Protects the active ingredient
Generic risk	Label and regimen dependent	Product-wide
Key limitation	Requires claimed disease, dose, cycle and combination	Depends on chemical claim scope and expiration

A generic applicant may face both types of patents. Avoiding the 7,968,569 regimen claims does not necessarily avoid the composition patent. Conversely, expiration or invalidity of the composition patent does not automatically eliminate liability under an unexpired method patent.

What is the litigation and settlement significance?

Celgene's Revlimid patent litigation created a negotiated generic-entry structure. Settlements reportedly authorized certain generic applicants to launch limited quantities before broader entry dates, with full competition tied to patent expiry or agreed licenses. The terms varied by applicant and patent family.

For diligence, the controlling documents are:

The relevant ANDA notice letter;
The complaint and asserted patent list;
The district court judgment;
Any Federal Circuit decision;
The settlement and license agreement;
The FDA approval letter;
The approved generic labeling; and
Current Orange Book patent data.

The patent number alone cannot establish whether a particular generic may launch. Launch rights can be applicant-specific and product-specific.

Does U.S. Patent 7,968,569 create biosimilar risk?

No. Lenalidomide is a small-molecule drug, not a biologic. The relevant competitors are ANDA-based generic applicants, not biosimilar applicants under the Public Health Service Act.

The applicable regulatory framework is the Hatch-Waxman Act. Generic applicants file ANDAs, submit bioequivalence data and address listed patents through Paragraph I, II, III, IV or section viii certifications, as applicable.

Key Takeaways

U.S. Patent 7,968,569 covers lenalidomide treatment of multiple myeloma with dexamethasone.
The central regimen is 5 to 25 mg of lenalidomide for 21 days followed by seven days of rest in a 28-day cycle.
Claim 13 specifically covers 25 mg on days 1 through 21 plus 40 mg of dexamethasone on days 1 through 4.
The patent covers relapsed, refractory and treatment-resistant multiple myeloma populations.
Oral capsules and tablets are expressly covered.
Claim 14 adds a specific excipient combination but is narrower than the principal regimen claims.
The patent is an Orange Book-listed method patent associated with Revlimid.
Its listed expiration falls in the December 2027 period, subject to controlling term data and any applicable extension.
Generic competition has been shaped by Paragraph IV litigation and applicant-specific settlements.
The patent does not replace the need to analyze the lenalidomide composition patent, formulation patents, manufacturing patents and settlement licenses.
Biosimilar analysis is not applicable; the competitive pathway is generic ANDA entry.

FAQs

Can a generic lenalidomide product avoid U.S. Patent 7,968,569 by using a different dose?

Potentially, but only if the proposed use, labeling and actual conduct avoid every limitation of the asserted claim. A dose outside the claimed range may not avoid other patents or other claims, particularly composition, formulation or disease-use patents.

Does a 21-days-on, seven-days-off regimen infringe without dexamethasone?

The answer depends on the asserted claim. Claims requiring combination with dexamethasone require that limitation. A method that omits dexamethasone may avoid those claims but remain exposed to other patents or other asserted claims.

Does claim 14 cover every Revlimid or generic lenalidomide capsule?

No. Claim 14 requires the recited lenalidomide, anhydrous lactose, microcrystalline cellulose, croscarmellose sodium and magnesium stearate composition. It does not cover every capsule formulation.

Is U.S. Patent 7,968,569 a patent on lenalidomide itself?

No. It is a method-of-treatment patent. The foundational chemical protection for lenalidomide must be analyzed separately.

Can a generic enter after FDA approval but before December 2027?

Possibly. Entry may occur under a settlement license, an authorized-generic arrangement, a court judgment, a patent expiration date different from the nominal date, or a successful noninfringement or invalidity outcome. FDA approval alone does not establish unrestricted commercial launch rights.

References

U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,968,569, Methods of treating multiple myeloma.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Court of Appeals for the Federal Circuit. (2019). Celgene Corp. v. Peter, 931 F.3d 1342.
U.S. District Court for the District of Delaware. (2018-2024). Celgene Corporation v. various ANDA applicants, patent litigation records involving Revlimid.
U.S. Food and Drug Administration. (2024). Revlimid (lenalidomide) prescribing information and Risk Evaluation and Mitigation Strategy materials.
U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,635,517, Substituted 2-(2,6-dioxopiperidin-3-yl)-isoindole-1,3-diones.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2105135	⤷ Start Trial	1590004-6	Sweden	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	C300717	Netherlands	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	CA 2015 00006	Denmark	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	92642	Luxembourg	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	C20150005 00140	Estonia	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,968,569

Summary for Patent: 7,968,569